A new MSS-CRC immunotherapy trial - NCT02903914.
A novel mechanism, an "arginase inhibitor" named "CB-1158". Arginase is immunosupressive and it has been known for years to be a clinical marker for CRC - so they are specifically recruiting MSS-CRC patients for an arm of the trial. I am glad for the steady increasing focus on MSS-CRC in immunotherapy clinical trials! My guess is that they will eventually test it in combination with PD1 in MSS-CRC patients but they are only testing CB-1158 alone to start (in CRC)...
https://clinicaltrials.gov/ct2/show/NCT ... 914&rank=1
-DK